Thyroid Transcription Factor-1 Expression in Advanced Non-Small Cell Lung Cancer: Impact on Survival Outcome |
Elsamany, Shereef Ahmed
(Department of Medical Oncology, Oncology Centre, King Abdulaziz Medical City)
Al-Fayea, Turki M (King Abdulaziz Medical City) Alzahrani, Abdullah Said (Department of Medical Oncology, Oncology Centre, King Abdulaziz Medical City) Abozeed, Waleed Nabeel (Department of Clinical Oncology, Mansoura University Hospital) Darwish, Waseem (King Abdulaziz Medical City) Farooq, Mian Usman (Department of Research, King Abdullah Medical City) Almadani, Ahmed Salahuddin (Department of Research, Um Alqora University) Bukhari, Esraa Ahmed (Department of Research, Um Alqora University) |
1 | Pelosi G, Fraggetta F, Pasini F, et al (2001). Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas ofthe lung. Am J Surg Pathol, 25, 363-72. DOI |
2 | Saad RS, Liu YL, Han H, Landreneau RJ, Silverman JF (2004). Prognostic significance of thyroid transcription factor-1 expression in both early-stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. Hum Pathol, 35, 3-7. DOI |
3 | Stenhouse G, Fyfe N, King G, Chapman A, Kerr KM (2004). Thyroid transcription factor 1 in pulmonary adenocarcinoma. J Clin Pathol, 57, 383-7. DOI |
4 | Sun JM, Han J, Ahn JS, Han JH, Ahn M (2011). Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol, 6, 1392-9. DOI |
5 | Tan D, Li Q, Deeb G, et al (2003). Thyroid transcription factor-1 expression prevalence and its clinical implications in nonsmall cell lung cancer: A high throughput tissue microarray and immunohistochemistry study. Hum Pathol, 34, 597-604. DOI |
6 | Tanaka H, Yanagisawa K, Shinjo K, et al (2007). Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res, 67, 6007-11. DOI |
7 | Wang JY, Cai Y (2013). Clinical observation and prognostic analysis of pemetrexed plus platinum as first-line treatment in patients with advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 6267-71. DOI ScienceOn |
8 | Zhan P, Qian Q, Wan B, Yan TD, Yu LK (2013). Prognostic value of TTF-1 expression in patients with non-small cell lung cancer: a meta-analysis. Transl Cancer Res, 2, 25-32. |
9 | Anagnostou VK, Syrigos KN, Bepler G, Homer RJ, Rimm DL (2009). Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol, 27, 271-8. DOI |
10 | Barlesi F, Pinot D, Legoffic A, et al (2005). Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung. Br J Cancer, 93, 450-2. DOI |
11 | Berghmans T, Paesmans M, Mascaux C, et al (2006). Thyroid transcription factor 1: a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol, 17, 1673-6. DOI |
12 | Hoffman PC, Mauer AM, Vokes EE (2000). Lung cancer. Lancet, 355, 479-85. DOI |
13 | Cao W, Li AW, Ren SX, et al (2014). Efficacy of first-line chemotherapy affects the second-line setting response in patients with advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 6799-804. DOI |
14 | Chung KP, Huang YT, Chang YL, et al (2012). Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment. Chest, 141, 420-8. DOI ScienceOn |
15 | Haque AK, Syed S, Lele SM, Freeman DH, Adegboyega PA (2002). Immunohistochemical study of thyroid transcription factor-1 and HER2/neu in non-small cell lung cancer: Strong thyroid transcription factor-1 expression predicts better survival. Appl Immunohistochem Mol Morphol, 10, 103-9. |
16 | Hotta K, Matsuo K, Ueoka H, et al (2004). Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: Reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol, 22, 3860-7. DOI |
17 | Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pac J Cancer Prev, 13, 301-4. DOI |
18 | Liu YC, Zhou SB, Gao F, et al (2013). Chemotherapy and late course three dimensional conformal radiotherapy for treatment of patients with stage III non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 2663-5. DOI ScienceOn |
19 | Martins SJ, Takagaki TY, Silva AG, et al (2009). Prognostic relevance of TTF-1 and MMP-9 expression in advanced lung adenocarcinoma. Lung Cancer, 64, 105-9. DOI |
![]() |